Cargando…

Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas

PURPOSE: To assess the diagnostic performance of Whole Body (WB)-MRI in comparison with 18F-Fluorodeoxyglucose-PET/CT (18F-FDG-PET/CT) in lymphoma staging and to assess whether quantitative metabolic parameters from 18F-FDG-PET/CT and Apparent Diffusion Coefficient (ADC) values are related. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Maccioni, Francesca, Alfieri, Giulia, Assanto, Giovanni Manfredi, Mattone, Monica, Gentiloni Silveri, Guido, Viola, Federica, De Maio, Alessandro, Frantellizzi, Viviana, Di Rocco, Alice, De Vincentis, Giuseppe, Pulsoni, Alessandro, Martelli, Maurizio, Catalano, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182138/
https://www.ncbi.nlm.nih.gov/pubmed/37145214
http://dx.doi.org/10.1007/s11547-023-01622-9
_version_ 1785041726594875392
author Maccioni, Francesca
Alfieri, Giulia
Assanto, Giovanni Manfredi
Mattone, Monica
Gentiloni Silveri, Guido
Viola, Federica
De Maio, Alessandro
Frantellizzi, Viviana
Di Rocco, Alice
De Vincentis, Giuseppe
Pulsoni, Alessandro
Martelli, Maurizio
Catalano, Carlo
author_facet Maccioni, Francesca
Alfieri, Giulia
Assanto, Giovanni Manfredi
Mattone, Monica
Gentiloni Silveri, Guido
Viola, Federica
De Maio, Alessandro
Frantellizzi, Viviana
Di Rocco, Alice
De Vincentis, Giuseppe
Pulsoni, Alessandro
Martelli, Maurizio
Catalano, Carlo
author_sort Maccioni, Francesca
collection PubMed
description PURPOSE: To assess the diagnostic performance of Whole Body (WB)-MRI in comparison with 18F-Fluorodeoxyglucose-PET/CT (18F-FDG-PET/CT) in lymphoma staging and to assess whether quantitative metabolic parameters from 18F-FDG-PET/CT and Apparent Diffusion Coefficient (ADC) values are related. MATERIALS AND METHODS: We prospectively enrolled patients with a histologically proven primary nodal lymphoma to  undergo 18F-FDG-PET/CT and WB-MRI, both performed within 15 days one from the other, either before starting treatment (baseline) or during treatment (interim). Positive and negative predictive values of WB-MRI for the identification of nodal and extra-nodal disease were measured. The agreement between WB-MRI and 18F-FDG-PET/CT for the identification of lesions and staging was assessed through Cohen's coefficient k and observed agreement. Quantitative parameters of nodal lesions derived from 18F-FDG-PET/CT and WB-MRI (ADC) were measured and the Pearson or Spearman correlation coefficient was used to assess the correlation between them. The specified level of significance was p ≤ 0.05. RESULTS: Among the 91 identified patients, 8 refused to participate and 22 met exclusion criteria, thus images from 61 patients (37 men, mean age 30.7 years) were evaluated. The agreement between 18F-FDG-PET/CT and WB-MRI for the identification of nodal and extra-nodal lesions was 0.95 (95% CI 0.92 to 0.98) and 1.00 (95% CI NA), respectively; for staging it was 1.00 (95% CI NA). A strong negative correlation was found between ADCmean and SUVmean of nodal lesions in patients evaluated at baseline (Spearman coefficient r(s) = − 0.61, p = 0.001). CONCLUSION: WB-MRI has a good diagnostic performance for staging of patients with lymphoma in comparison with 18F-FDG-PET/CT and is a promising technique for the quantitative assessment of disease burden in these patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11547-023-01622-9.
format Online
Article
Text
id pubmed-10182138
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-101821382023-05-14 Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas Maccioni, Francesca Alfieri, Giulia Assanto, Giovanni Manfredi Mattone, Monica Gentiloni Silveri, Guido Viola, Federica De Maio, Alessandro Frantellizzi, Viviana Di Rocco, Alice De Vincentis, Giuseppe Pulsoni, Alessandro Martelli, Maurizio Catalano, Carlo Radiol Med Diagnostic Imaging in Oncology PURPOSE: To assess the diagnostic performance of Whole Body (WB)-MRI in comparison with 18F-Fluorodeoxyglucose-PET/CT (18F-FDG-PET/CT) in lymphoma staging and to assess whether quantitative metabolic parameters from 18F-FDG-PET/CT and Apparent Diffusion Coefficient (ADC) values are related. MATERIALS AND METHODS: We prospectively enrolled patients with a histologically proven primary nodal lymphoma to  undergo 18F-FDG-PET/CT and WB-MRI, both performed within 15 days one from the other, either before starting treatment (baseline) or during treatment (interim). Positive and negative predictive values of WB-MRI for the identification of nodal and extra-nodal disease were measured. The agreement between WB-MRI and 18F-FDG-PET/CT for the identification of lesions and staging was assessed through Cohen's coefficient k and observed agreement. Quantitative parameters of nodal lesions derived from 18F-FDG-PET/CT and WB-MRI (ADC) were measured and the Pearson or Spearman correlation coefficient was used to assess the correlation between them. The specified level of significance was p ≤ 0.05. RESULTS: Among the 91 identified patients, 8 refused to participate and 22 met exclusion criteria, thus images from 61 patients (37 men, mean age 30.7 years) were evaluated. The agreement between 18F-FDG-PET/CT and WB-MRI for the identification of nodal and extra-nodal lesions was 0.95 (95% CI 0.92 to 0.98) and 1.00 (95% CI NA), respectively; for staging it was 1.00 (95% CI NA). A strong negative correlation was found between ADCmean and SUVmean of nodal lesions in patients evaluated at baseline (Spearman coefficient r(s) = − 0.61, p = 0.001). CONCLUSION: WB-MRI has a good diagnostic performance for staging of patients with lymphoma in comparison with 18F-FDG-PET/CT and is a promising technique for the quantitative assessment of disease burden in these patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11547-023-01622-9. Springer Milan 2023-05-05 2023 /pmc/articles/PMC10182138/ /pubmed/37145214 http://dx.doi.org/10.1007/s11547-023-01622-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Diagnostic Imaging in Oncology
Maccioni, Francesca
Alfieri, Giulia
Assanto, Giovanni Manfredi
Mattone, Monica
Gentiloni Silveri, Guido
Viola, Federica
De Maio, Alessandro
Frantellizzi, Viviana
Di Rocco, Alice
De Vincentis, Giuseppe
Pulsoni, Alessandro
Martelli, Maurizio
Catalano, Carlo
Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
title Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
title_full Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
title_fullStr Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
title_full_unstemmed Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
title_short Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
title_sort whole body mri with diffusion weighted imaging versus 18f-fluorodeoxyglucose-pet/ct in the staging of lymphomas
topic Diagnostic Imaging in Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182138/
https://www.ncbi.nlm.nih.gov/pubmed/37145214
http://dx.doi.org/10.1007/s11547-023-01622-9
work_keys_str_mv AT maccionifrancesca wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT alfierigiulia wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT assantogiovannimanfredi wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT mattonemonica wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT gentilonisilveriguido wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT violafederica wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT demaioalessandro wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT frantellizziviviana wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT diroccoalice wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT devincentisgiuseppe wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT pulsonialessandro wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT martellimaurizio wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas
AT catalanocarlo wholebodymriwithdiffusionweightedimagingversus18ffluorodeoxyglucosepetctinthestagingoflymphomas